Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Importance Imaging biomarkers in Parkinson disease (PD) are increasingly important for
monitoring progression in clinical trials and also have the potential to improve clinical care …

Parkinson's disease (PD) is the second most common neurodegenerative disease after
Alzheimer's disease (AD). It is characterized by a progressive loss of dopaminergic neurons …

Parkinson disease is characterized by dopaminergic cell loss in the substantia nigra of the
midbrain. There are various imaging markers for Parkinson disease. Recent advances in …

In the long-term, with progression of the illness, Parkinson's disease dementia affects up to
90% of patients with Parkinson's disease. With increasing life expectancy in western …

The differential diagnosis of parkinsonian syndromes is considered one of the most
challenging in neurology and error rates in the clinical diagnosis can be high even at …

Recent research highlights the association of gait and cognition in older adults but a
stronger understanding is needed to discern coincident pathophysiology, patterns of …

Cognitive impairment in patients with Parkinson's disease is gaining increased clinical
significance owing to the relative success of therapeutic approaches to the motor symptoms …

Dementia has been increasingly more recognized to be a common feature in patients with
Parkinson's disease (PD), especially in old age. Specific criteria for the clinical diagnosis of …

Dementia is one of the most common and important aspects of Parkinson's disease and has
consequences for patients and caregivers, and has health-related costs. Mild cognitive …